Cytarabine
Showing 51 - 75 of 1,522
Acute Myeloid Leukemia Trial in Baltimore, New York, Chapel Hill (Alvocidib, Cytarabine, Daunorubicin)
Cytarabine+Thiotepa + Fludarabine + Busulfan, T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Trial in Hangzhou
Recruiting
- Cytarabine+Thiotepa + Fludarabine + Busulfan
- T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
- cytarabine+thiotepa+ fludarabine + busulfan
-
Hangzhou, ChinaThe First Affiliated Hospital, College of Medicine, Zhejiang Uni
Oct 26, 2022
Recurrent Acute Myeloid Leukemia Trial in United States (Enasidenib Mesylate, Liposome-encapsulated Daunorubicin-Cytarabine)
Suspended
- Recurrent Acute Myeloid Leukemia
- Enasidenib Mesylate
- Liposome-encapsulated Daunorubicin-Cytarabine
-
Los Angeles, California
- +3 more
Sep 27, 2022
Acute Myeloid Leukemia, in Relapse Trial in Baltimore, Chapel Hill (pembrolizumab,)
Active, not recruiting
- Acute Myeloid Leukemia, in Relapse
-
Baltimore, Maryland
- +1 more
Aug 10, 2022
Refractory Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia Trial in Kansas City, Baltimore (Fosciclopirox,
Recruiting
- Refractory Acute Myeloid Leukemia
- Recurrent Acute Myeloid Leukemia
- Fosciclopirox
- Fosciclopirox + Cytarabine
-
Kansas City, Kansas
- +1 more
May 28, 2022
Relapsed Adult AML Trial in Germany (Venetoclax Oral Tablet)
Recruiting
- Relapsed Adult AML
- Refractory AML
- Venetoclax Oral Tablet
-
Augsburg, Germany
- +11 more
Jan 11, 2023
Mantle Cell Lymphoma Trial in Saint Louis (Bendamustine, Rituximab, Acalabrutinib)
Active, not recruiting
- Mantle Cell Lymphoma
- Bendamustine
- +7 more
-
Saint Louis, MissouriWashington University School of Medicine
Feb 2, 2022
Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent,
Not yet recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- +4 more
- Trametinib
- +4 more
-
Utrecht, NetherlandsPrincess Máxima Center for Pediatric Oncology
Dec 13, 2022
Acute Myeloid Leukemia, Blasts 20 Percent or More of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome Trial in
Recruiting
- Acute Myeloid Leukemia
- +7 more
- Cladribine
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Dec 7, 2022
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b) Trial
Completed
- Adult Acute Megakaryoblastic Leukemia (M7)
- +13 more
- Sirolimus
- +2 more
-
Philadelphia, PennsylvaniaThomas Jefferson University
Feb 2, 2023
Acute Myeloid Leukemia Trial in Shenyang (rhTPO, Decitabine)
Recruiting
- Acute Myeloid Leukemia
-
Shenyang, Liaoning, ChinaShengJing Hospital of China Medical University
May 16, 2022
Acute Lymphocytic Leukemia, Adult Lymphoblastic Lymphoma Trial in United States (DNR, VCR, PEG-asp)
Terminated
- Acute Lymphocytic Leukemia
- Adult Lymphoblastic Lymphoma
- DNR
- +12 more
-
La Jolla, California
- +3 more
Apr 26, 2022
FLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive, Recurrent Acute Myeloid Leukemia Trial in Houston
Active, not recruiting
- FLT3 Gene Mutation Negative
- +7 more
- Azacitidine
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Nov 16, 2022
Acute Myeloid Leukemia With KMT2A Rearrangement, Acute Myeloid Leukemia With NPM1 Mutation Trial (Biospecimen Collection, Bone
Not yet recruiting
- Acute Myeloid Leukemia With KMT2A Rearrangement
- Acute Myeloid Leukemia With NPM1 Mutation
- Biospecimen Collection
- +7 more
- (no location specified)
Jun 1, 2023
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic
Completed
- Adult Acute Megakaryoblastic Leukemia (M7)
- +15 more
- trebananib
- +3 more
-
Buffalo, New York
- +1 more
Sep 8, 2022
Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia Trial in Memphis (drug, biological, radiation)
Not yet recruiting
- Refractory Acute Lymphoblastic Leukemia
- Relapsed Acute Lymphoblastic Leukemia
- Venetoclax
- +16 more
-
Memphis, TennesseeSt. Jude Children's Research Hospital
Aug 23, 2022
Acute Myeloid Leukemia Trial in Seattle (drug, biological, other)
Active, not recruiting
- Acute Myeloid Leukemia
- Cladribine
- +5 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Oct 10, 2022
Acute Myelogenous Leukemia, AML Trial in Worldwide (Venetoclax, Cytarabine)
Completed
- Acute Myelogenous Leukemia
- AML
- Venetoclax
- Cytarabine
-
Kansas City, Kansas
- +8 more
Aug 3, 2022
Drug/Agent Toxicity by Tissue/Organ, Leukemia, MDS Trial in Chicago, Kankakee (amifostine trihydrate, cytarabine, mitoxantrone
Withdrawn
- Drug/Agent Toxicity by Tissue/Organ
- +3 more
- amifostine trihydrate
- +2 more
-
Chicago, Illinois
- +3 more
Jan 31, 2023
Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Trial in
Recruiting
- Acute Biphenotypic Leukemia
- +13 more
- Cladribine
- +6 more
-
Houston, TexasM D Anderson Cancer Center
Jan 19, 2023
Acute Myelogenous Leukemia, AML, Advanced MDS Trial in Miami (Pevonedistat, Cytarabine)
Completed
- Acute Myelogenous Leukemia
- +3 more
- Pevonedistat
- Cytarabine
-
Miami, FloridaUniversity of Miami
Dec 7, 2021
Lymphoma, Autologous Hematopoietic Stem Cell Transplantation Trial in Xi'an (Improved BEAM regimen)
Not yet recruiting
- Lymphoma
- Autologous Hematopoietic Stem Cell Transplantation
- Improved BEAM regimen
-
Xi'an, Shaanxi, ChinaFirst Affiliated Hospital of Xi'an Jiaotong University
Dec 26, 2022
Minimal Residual Disease, Leukemia, Lymphoblastic, Acute, Leukemia, Myelogenous, Acute Trial in Charlotte, Seattle (Clofarabine,
Terminated
- Minimal Residual Disease
- +2 more
- Clofarabine
- +3 more
-
Charlotte, North Carolina
- +1 more
Oct 4, 2021